Glox Therapeutics Appoints Dr. Michael Murray as Chair and Dr. Nel Moore to Scientific Advisory Board

Glox Therapeutics Appoints Dr. Michael Murray as Chair and Dr. Nel Moore to Scientific Advisory Board Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced the appointment of Dr. Michael Murray as Chair of…

Read MoreGlox Therapeutics Appoints Dr. Michael Murray as Chair and Dr. Nel Moore to Scientific Advisory Board

Silobreaker Partners with Health-ISAC to Offer Free Trial of Threat Intelligence Platform

Silobreaker Partners with Health-ISAC to Offer Free Trial of Threat Intelligence Platform Silobreaker, a leading security and threat intelligence technology company, has announced a new partnership with the Health Information Sharing and Analysis Center (Health-ISAC) as a Community Services Partner.…

Read MoreSilobreaker Partners with Health-ISAC to Offer Free Trial of Threat Intelligence Platform

Blackstone Life Sciences and Anthos Therapeutics Reach Deal for Novartis to Acquire Anthos for up to $3.1 Billion

Blackstone Life Sciences and Anthos Therapeutics Reach Deal for Novartis to Acquire Anthos for up to $3.1 Billion Blackstone Life Sciences and Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transformative therapies for cardiometabolic diseases, have announced a significant…

Read MoreBlackstone Life Sciences and Anthos Therapeutics Reach Deal for Novartis to Acquire Anthos for up to $3.1 Billion

LIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction

LIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction LIB Therapeutics Inc., a late-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for Lerodalcibep. This…

Read MoreLIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction

Arrowhead Pharmaceuticals Closes Global License and Collaboration with Sarepta Therapeutics

Arrowhead Pharmaceuticals Closes Global License and Collaboration with Sarepta Therapeutics Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the successful closing of its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). The agreement, initially announced on November 26, 2024,…

Read MoreArrowhead Pharmaceuticals Closes Global License and Collaboration with Sarepta Therapeutics

GeneDx Integrates with Epic to Expand Genome and Exome Sequencing for Faster Diagnosis and Treatment

GeneDx Integrates with Epic to Expand Genome and Exome Sequencing for Faster Diagnosis and Treatment GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, announced the launch of its integration with Aura, Epic’s specialty diagnostics suite. This…

Read MoreGeneDx Integrates with Epic to Expand Genome and Exome Sequencing for Faster Diagnosis and Treatment

Incyte Reports Q4 and Year-End 2024 Results, Provides 2025 Financial Outlook and R&D Milestones

Incyte Reports Q4 and Year-End 2024 Results, Provides 2025 Financial Outlook and R&D Milestones Incyte (Nasdaq: INCY) has announced its financial results for the fourth quarter and full year ended December 31, 2024, along with its financial guidance for 2025.…

Read MoreIncyte Reports Q4 and Year-End 2024 Results, Provides 2025 Financial Outlook and R&D Milestones